Plus   Neg

Stock Alert: Aptevo Jumps 15% On Positive Data In Blood Cancer Trial

Shares of Aptevo Therapeutics Inc. (APVO) are gaining over 15% on Tuesday morning after the clinical-stage biotechnology company announced first complete remission in ongoing Phase 1 trial for blood cancer.

APVO is currently trading at $7.30, up $1.00 or 15.87%, on the Nasdaq.

Aptevo Therapeutics, a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR platform, announced that, based on preliminary data, a patient in cohort 6 of ongoing APVO436 Phase 1 clinical trial has shown complete remission.

APVO436 is a novel anti-CD123 x anti-CD3 targeted investigational bispecific antibody therapy being evaluated for the treatment of acute myeloid leukemia and myelodysplastic syndrome.

Acute myeloid leukemia is a type of cancer of the blood and bone marrow with excess immature white blood cells. Myelodysplastic syndrome are a group of disorders caused when something disrupts the production of blood cells.

According to Webmd, complete remission means that tests, physical exams, and scans show that all signs of your cancer are gone. Some doctors also refer to complete remission as "no evidence of disease. That doesn't mean you are cured.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Best Buy said it is partnering Popsockets to bring products designed by teens from the company's community programs to its store shelves. The electronics retailer will sell the teen-designed PopGrips in its stores as part of its "Black History Month" campaign. The campaign is intended to celebrate and encourage young artists. Goldman Sachs Group Inc. (GS) on Tuesday reported a fourth-quarter profit that more than doubled from last year, reflecting a surge in investment banking revenues and lower provisions for bad loans. Net revenues for the quarter rose 18 percent. Both quarterly earnings per share and revenues topped analysts' expectations. U.S. holiday retail sales in 2020 were unexpectedly high compared to last year and came in significantly higher than the previous forecast, according to the National Retail Federation or NRF. Retail sales for the November-December 2020 holiday season grew 8.3 percent from the prior-year period to $789.4 billion. The figures exclude automobile dealers, gasoline stations and restaurants.
Follow RTT